MIT Technology Review Subscribe

Fending Off the Flu

If H1N1 vaccine supplies fall short, people may have to turn to supplements, statins, and laser-coupled vaccination.

A number of common supplements and drugs can boost the immune system’s ability to ward off the flu and reduce symptoms once you have it, said Jeffrey Gelfand, a physician at Massachusetts General Hospital at the CIMIT (Center for Integration of Medicine and Innovative Technology) Innovation Congress this morning in Boston. Gelfand suggested that in the absence of adequate supplies of vaccine against the H1N1 flu strain, we’ll need to turn to less conventional measures. Clinical research shows that L-theanine, which is found in tea, and quercetin, a plant polyphenol, can reduce chances of getting an upper respiratory infection, he said. Both are available at stores that sell vitamin supplements.

Statins, the cholesterol-lowering blockbuster drug, can reduce symptoms of the flu, especially in younger people, the group hardest hit by H1N1. The drugs, many of which are available generically, reduce the “cytokine storm”–part of the immune reaction that occurs during sepsis and influenza infection. “I believe this could significantly reduce mortality,” said Gelfand.

Advertisement

Gelfand also said that changing our approach to vaccination could help extend limited vaccine supplies. One method currently under study is delivering vaccines to the skin, rather than to the muscle, as is done with current injections. Directly targeting the skin enhances the response from immune cells in the skin. His team is testing a laser-coupled injection system, in which a precise dose of laser light is used to briefly irritate the skin, attracting the target immune cells even more effectively. Initial studies show that this approach generates the same antibody response with only 20 percent of the amount of vaccine.

This story is only available to subscribers.

Don’t settle for half the story.
Get paywall-free access to technology news for the here and now.

Subscribe now Already a subscriber? Sign in
You’ve read all your free stories.

MIT Technology Review provides an intelligent and independent filter for the flood of information about technology.

Subscribe now Already a subscriber? Sign in
This is your last free story.
Sign in Subscribe now

Your daily newsletter about what’s up in emerging technology from MIT Technology Review.

Please, enter a valid email.
Privacy Policy
Submitting...
There was an error submitting the request.
Thanks for signing up!

Our most popular stories

Advertisement